JERINI COMPLETES RANDOMIZATION IN FAST 1 TRIAL

A A

Jerini has randomized the last patient in its Phase III clinical trial (FAST 1) of Icatibant for the treatment of hereditary angioedema (HAE).

A total of 56 patients were treated at 26 clinical sites in the U.S., Canada, Australia, and Latin America in a double-blind, placebo-controlled study.

Patients participating in the FAST 1 and FAST 2 randomization phase are eligible to receive Icatibant in the ongoing open-label study phase. Filing of a marketing authorization application with Icatibant for the treatment of HAE is planned for the end of 2006.